Prostate specific membrane antigen binding fibronectin type iii domains

Patent metadata

Field	Value
Publication number	US-12054534-B2
Application number	US-202016949078-A
Country	US
Kind code	B2
Filing date	Oct 13, 2020
Priority date	May 6, 2015
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

First claim

What is claimed:

1. An anti-human prostate specific membrane antigen (PSMA) binding polypeptide comprising the amino acid sequence of SEQ ID NO: 88 and optionally an additional methionine at the N-terminus.

2. The polypeptide of claim 1 conjugated to at least one second molecule.

3. The polypeptide of claim 2 , wherein said at least one second molecule is a cytotoxic agent, a detectable label, polyethylene glycol, or a nucleic acid.

4. The polypeptide of claim 3 , wherein the cytotoxic agent is auristatin, monomethyl auristatin phenylalanine, dolostatin, a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin, or a radioactive isotope.

5. The polypeptide of claim 3 , wherein the detectable label is a radioactive isotope, a magnetic bead, a metallic bead, a colloidal particle, a fluorescent dye, an electron-dense reagent, an enzyme, biotin, digoxigenin, or a hapten.

6. The polypeptide of claim 2 , wherein said at least one second molecule is a serum albumin polypeptide, an antibody that specifically binds to a serum albumin polypeptide, or an immunoglobulin Fc region.

7. A polynucleotide comprising a nucleotide sequence encoding the polypeptide of claim 1 .

8. A vector comprising the polynucleotide of claim 7 .

9. An isolated host cell comprising the vector of claim 8 .

10. A method of producing a polypeptide comprising the amino acid sequence of SEQ ID NO: 88 and optionally an additional methionine at the N-terminus, said method comprising culturing the host cell of claim 9 under conditions such that the polypeptide is expressed and optionally purifying the polypeptide.

11. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

12. A diagnostic kit comprising the polypeptide of claim 1 .

13. A diagnostic agent comprising the polypeptide of claim 1 .

14. A method of detecting a human PSMA polypeptide comprising SEQ ID NO: 144 in a biological sample, said method comprising contacting a biological sample with an anti-human PSMA binding polypeptide according to claim 1 and detecting any resulting complexes comprising the human PSMA polypeptide and said anti-human PSMA binding polypeptide.

Assignees

• Janssen Biotech Inc

Inventors

• Cardoso Rosa
• Diem Michael
• Goldberg Shalom
• Hyun Linus
• Jacobs Steven
• Klein Donna
• O'Neil Karyn
• Spinka-Doms Tracy

Classifications

• G01N33/57555

  of the prostate · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K51/08

  Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title